Cognition Therapeutics reported on 2nd quarter financial results and business updates including optimistic advancements in clinical trials.
CogRx
Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes
Analytic results in a study of Cognition Therapeutic’s CT1812, a drug targeting mild-to-moderate Alzheimer’s disease, indicates a reduction in the YKL-40, a biomarker for inflammation associated with Alzheimer’s.
Cognition Therapeutics Reports Year End 2021 Financial Results
Cognition Therapeutics has a transformative 2021 with positive performance addressing age related degenerative diseases and disorders of the central nervous system.
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today provided a summary of the Company’s 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead.…
Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone
PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced the addition of Ellen B.…
Sofia Fund Portfolio Earns Returns as Two Portfolio Companies Move to Next Stage of Growth
Cognitive Therapeutics goes public, Explorer Surgical acquired
MINNEAPOLIS (Oct. 25, 2021) – Sofia Fund, the angel investment firm focused exclusively on women-led companies, announces new milestones: two of its portfolio companies have progressed onto their next stages of growth, providing returns for Sofia’s group of investors.…
Sofia portfolio company Cognition Therapeutics goes public
Women-led biopharmaceutical company Cognition Therapeutics newly public stock started trading Oct. 8. CGTX (new NASDAQ ticker) innovates therapeutics that target age-related degenerative diseases and disorders. See the news here: https://ir.cogrx.com/news-releases/news-release-details/cognition-therapeutics-announces-pricing-upsized-initial-public…
Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease
Mutation Validates Cognition Approach to Oligomer Displacement
Pittsburgh, October 19, 2020 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that a peer-reviewed manuscript, entitled, “Icelandic Mutant Human Amyloid-β 1-42 Peptide Forms Fewer Oligomers with Lower Binding Affinity than Wild-Type Peptide,” has been published online in the Journal of Neurochemistry (doi:10.1111/jnc.15212).…
Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study
Pittsburgh, August 27, 2020 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has dosed the first patient in the SEQUEL (Study of EEG QUantification with ELayta) Study of CT1812 (Elayta™) in adults with mild-to-moderate Alzheimer’s disease.…
Cognition Therapeutics Receives $75.8 Million NIA Grant
Sofia portfolio company Cognition Therapeutics awarded $75.8M in competitive grant process, to study efficacy of its technology with early Alzheimer’s patients
New York, June 08, 2020 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a grant (number R01AG065248) expected to total $75.8 million over five years to support a 540-patient Phase 2 study of CT1812 in individuals with early Alzheimer’s disease.…